189 related articles for article (PubMed ID: 17803969)
1. Lipid rafts and metabolic energy differentially determine uptake of anti-cancer alkylphospholipids in lymphoma versus carcinoma cells.
Vink SR; van der Luit AH; Klarenbeek JB; Verheij M; van Blitterswijk WJ
Biochem Pharmacol; 2007 Nov; 74(10):1456-65. PubMed ID: 17803969
[TBL] [Abstract][Full Text] [Related]
2. A new class of anticancer alkylphospholipids uses lipid rafts as membrane gateways to induce apoptosis in lymphoma cells.
van der Luit AH; Vink SR; Klarenbeek JB; Perrissoud D; Solary E; Verheij M; van Blitterswijk WJ
Mol Cancer Ther; 2007 Aug; 6(8):2337-45. PubMed ID: 17699729
[TBL] [Abstract][Full Text] [Related]
3. Alkylphospholipids inhibit capillary-like endothelial tube formation in vitro: antiangiogenic properties of a new class of antitumor agents.
Zerp SF; Vink SR; Ruiter GA; Koolwijk P; Peters E; van der Luit AH; de Jong D; Budde M; Bartelink H; van Blitterswijk WJ; Verheij M
Anticancer Drugs; 2008 Jan; 19(1):65-75. PubMed ID: 18043131
[TBL] [Abstract][Full Text] [Related]
4. In vitro and In vivo selective antitumor activity of Edelfosine against mantle cell lymphoma and chronic lymphocytic leukemia involving lipid rafts.
Mollinedo F; de la Iglesia-Vicente J; Gajate C; Estella-Hermoso de Mendoza A; Villa-Pulgarin JA; de Frias M; Roué G; Gil J; Colomer D; Campanero MA; Blanco-Prieto MJ
Clin Cancer Res; 2010 Apr; 16(7):2046-54. PubMed ID: 20233887
[TBL] [Abstract][Full Text] [Related]
5. Lipid raft-targeted therapy in multiple myeloma.
Mollinedo F; de la Iglesia-Vicente J; Gajate C; Estella-Hermoso de Mendoza A; Villa-Pulgarin JA; Campanero MA; Blanco-Prieto MJ
Oncogene; 2010 Jul; 29(26):3748-57. PubMed ID: 20418917
[TBL] [Abstract][Full Text] [Related]
6. Resistance to alkyl-lysophospholipid-induced apoptosis due to downregulated sphingomyelin synthase 1 expression with consequent sphingomyelin- and cholesterol-deficiency in lipid rafts.
Van der Luit AH; Budde M; Zerp S; Caan W; Klarenbeek JB; Verheij M; Van Blitterswijk WJ
Biochem J; 2007 Jan; 401(2):541-9. PubMed ID: 17049047
[TBL] [Abstract][Full Text] [Related]
7. Anticancer alkylphospholipids: mechanisms of action, cellular sensitivity and resistance, and clinical prospects.
van Blitterswijk WJ; Verheij M
Curr Pharm Des; 2008; 14(21):2061-74. PubMed ID: 18691116
[TBL] [Abstract][Full Text] [Related]
8. Proapoptotic role of Hsp90 by its interaction with c-Jun N-terminal kinase in lipid rafts in edelfosine-mediated antileukemic therapy.
Nieto-Miguel T; Gajate C; González-Camacho F; Mollinedo F
Oncogene; 2008 Mar; 27(12):1779-87. PubMed ID: 17891170
[TBL] [Abstract][Full Text] [Related]
9. Antitumoral alkylphospholipids alter cell lipid metabolism.
Marco C; Ríos-Marco P; Jiménez-López JM; Segovia JL; Carrasco MP
Anticancer Agents Med Chem; 2014 May; 14(4):545-58. PubMed ID: 24628237
[TBL] [Abstract][Full Text] [Related]
10. Edelfosine and miltefosine effects on lipid raft properties: membrane biophysics in cell death by antitumor lipids.
Castro BM; Fedorov A; Hornillos V; Delgado J; Acuña AU; Mollinedo F; Prieto M
J Phys Chem B; 2013 Jul; 117(26):7929-40. PubMed ID: 23738749
[TBL] [Abstract][Full Text] [Related]
11. Differential regulation of cell death in head and neck cell carcinoma through alteration of cholesterol levels in lipid rafts microdomains.
Bionda C; Athias A; Poncet D; Alphonse G; Guezguez A; Gambert P; Rodriguez-Lafrasse C; Ardail D
Biochem Pharmacol; 2008 Feb; 75(3):761-72. PubMed ID: 17996216
[TBL] [Abstract][Full Text] [Related]
12. Anticancer mechanisms and clinical application of alkylphospholipids.
van Blitterswijk WJ; Verheij M
Biochim Biophys Acta; 2013 Mar; 1831(3):663-74. PubMed ID: 23137567
[TBL] [Abstract][Full Text] [Related]
13. Changes of intracellular calcium, fatty acids and phospholipids during miltefosine-induced apoptosis monitored by fluorescence- and 13C NMR-spectroscopy.
Henke J; Engelmann J; Kutscher B; Nssner G; Engel J; Voegeli R; Leibfritz D
Anticancer Res; 1999; 19(5B):4027-32. PubMed ID: 10628349
[TBL] [Abstract][Full Text] [Related]
14. Fas/CD95 down-regulation in lymphoma cells through acquired alkyllysophospholipid resistance: partial role of associated sphingomyelin deficiency.
van Blitterswijk WJ; Klarenbeek JB; van der Luit AH; Alderliesten MC; van Lummel M; Verheij M
Biochem J; 2009 Dec; 425(1):225-34. PubMed ID: 19824885
[TBL] [Abstract][Full Text] [Related]
15. The anti-tumor alkylphospholipid perifosine is internalized by an ATP-dependent translocase activity across the plasma membrane of human KB carcinoma cells.
Muñoz-Martínez F; Torres C; Castanys S; Gamarro F
Biochim Biophys Acta; 2008 Feb; 1778(2):530-40. PubMed ID: 18005660
[TBL] [Abstract][Full Text] [Related]
16. Alkylphospholipids reversibly open epithelial tight junctions.
Leroy A; de Bruyne GK; Oomen LC; Mareel MM
Anticancer Res; 2003; 23(1A):27-32. PubMed ID: 12680191
[TBL] [Abstract][Full Text] [Related]
17. Disruption of cellular cholesterol transport and homeostasis as a novel mechanism of action of membrane-targeted alkylphospholipid analogues.
Carrasco MP; Jiménez-López JM; Ríos-Marco P; Segovia JL; Marco C
Br J Pharmacol; 2010 May; 160(2):355-66. PubMed ID: 20423345
[TBL] [Abstract][Full Text] [Related]
18. Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts.
Gajate C; Mollinedo F
Blood; 2007 Jan; 109(2):711-9. PubMed ID: 17003375
[TBL] [Abstract][Full Text] [Related]
19. Lipid rafts as major platforms for signaling regulation in cancer.
Mollinedo F; Gajate C
Adv Biol Regul; 2015 Jan; 57():130-46. PubMed ID: 25465296
[TBL] [Abstract][Full Text] [Related]
20. Lipid raft connection between extrinsic and intrinsic apoptotic pathways.
Gajate C; Gonzalez-Camacho F; Mollinedo F
Biochem Biophys Res Commun; 2009 Mar; 380(4):780-4. PubMed ID: 19338752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
